Heart Function in Cancer Patients: Nivolumab and Pembrolizumab

We are studying how immunotherapy treatments affect heart function in patients with cancer. This includes monitoring changes in heart performance and rhythm during treatment.

3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInjectionCardiologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Nivolumab
Nivolumab is a substance that helps the immune system recognize and attack certain cancers.
Pembrolizumab
Pembrolizumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein called PD-1.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Regional De Marseille
Cardiologie
Septèmes-les-Vallons, France
Sponsor: Centre Hospitalier Regional De Marseille
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.